Venture-Backed Life Science Companies Hit 7 Year Highs in Large Acquisitions7/19/2012 08:00:00 AM Company News
Silicon Valley Bank Study of Life Science M&A Exits Reveals Improving Trends for Life Science Investment
SANTA CLARA, Calif. – July 19, 2012 – Silicon Valley Bank, financial partner to technology and life science companies and their investors worldwide, released a today that examines the merger and acquisition behavior of private, venture capital-backed biotech and medical device companies.
Based on an analysis of private merger or acquisition transactions of US venture capital-backed companies since 2005, Silicon Valley Bank found a rebound in "Big Exits" among life science companies. Big Exits were defined as acquisitions where the upfront payment totaled in excess of $50 million for device companies and $75 million for biotech companies:
• 35 Big Exits in 2011: seven-year high • $12.5 billion invested in life science: seven-year high • Increased upfront deal values • Indications receiving the largest investments since 2005 • Biotech: Oncology, CNS, Anti-Infectives
• Device: Diagnostics, Orthopedics, Cardiovascular• Sectors with the highest multiples, versus dollars deployed since 2005 • Biotech: Respiratory, Cardiovascular,...Read More